Significant skin clearance was demonstrated in adolescents (primary endpoint; P<0.001)1-3,a
|Achieved clear or almost‑clear skin (IGA 0 or 1)||24%||2%|
aResponder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2 points on a 0‑4 scale at Week 16 (primary efficacy outcome).
bFull Analysis Set includes all subjects randomized.
cAdolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1